Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Merck Loses $473M Tax Appeal in Schering Case

By Pharmaceutical Processing | June 21, 2011

 

TRENTON,
N.J. (AP) — A three-judge federal
appeals court panel on Monday rejected an attempt by drugmaker Merck & Co.
to win a refund of nearly $500 million in taxes assessed two decades ago.

The Third Circuit Court of Appeals ruled Merck’s
Schering-Plough unit was not entitled to a refund of $473 million in taxes,
affirming the April 2010 ruling of U.S. District Judge Katherine S. Hayden.
Merck, of Whitehouse Station,
N.J., had appealed that ruling.

Schering-Plough had argued that funds it received through
two transactions involving foreign subsidiaries and a Dutch bank were not
immediately taxable in full as proceeds of loans.

Schering-Plough, which became part of Merck in November
2009, also argued that the U.S. Internal Revenue Service had not assessed taxes
on another taxpayer who engaged in similar transactions.

“We are disappointed with the court’s decision denying
our request for a new trial. We are reviewing the court’s decision and
considering our options,” Merck said in a statement Monday.

The case involves Swiss subsidiaries, Scherico and Limited,
owned by Schering-Plough in the early 1990s. They conducted significant
manufacturing in Ireland,
which then had a favorable corporate income tax, and had earnings of roughly $1
billion not yet been taxed in the U.S.

According to the appeals court ruling, Schering-Plough
executed a complex “scheme involving interest-rate swaps” over
multiple years among Schering, the Scherico subsidiary and then a third one
called Essex Chemie AG, and a Dutch bank. Schering-Plough later reported the
transactions as sales and repatriated about $690 million from its subsidiaries.

After a 2004 audit, the IRS assessed Schering-Plough for
underpaying nearly $473 million in taxes for 1989, 1991 and 1992, ruling those
transactions were loans, not sales.

Monday’s ruling, by Judges Fuentes, Smith and Greenberg,
concluded the federal court “correctly found that the transactions were in
substance loans, not sales.”

The 30-page ruling also rejected Schering-Plough’s
contention that it was unfair for the IRS to treat it differently than another
corporate taxpayer.

“To the extent that the IRS pursued Schering-Plough
more vigorously because Schering-Plough had a history of failing to comply with
the tax laws, this represents commendable agency diligence in the light of past
experience, not some kind of impermissible bias against Schering-Plough,”
the appellate judges wrote.

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE